STOCK TITAN

Enhabit SEC Filings

EHAB NYSE

Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Medicare reimbursement tables, patient-day metrics, and hospice turnover data are scattered across hundreds of pages of Enhabit’s disclosures. If parsing those figures in the latest Enhabit annual report 10-K simplified seems daunting, you’re not alone. Healthcare accounting rules create footnotes that read like another language. Stock Titan’s AI turns that language into clear insights, making Enhabit SEC filings explained simply. Whether you’re scanning for regulatory risks or auditing segment margins, our platform surfaces what matters before you wade through dense jargon.

Need the next Enhabit quarterly earnings report 10-Q filing or an alert on Enhabit Form 4 insider transactions real-time? Our engine pulls every document the moment it hits EDGAR and delivers AI-powered summaries in seconds. Investors searching for:

  • Enhabit insider trading Form 4 transactions
  • Enhabit proxy statement executive compensation
  • Enhabit 8-K material events explained
  • Enhabit earnings report filing analysis

receive a single dashboard that connects each form to real questions: What did executives buy, how did home-health margins shift, and did CMS rule changes impact revenue guidance?

Understanding Enhabit SEC documents with AI also means context. Our tools highlight hospice census trends, regional payor mixes, and quality-of-care metrics buried deep in footnotes. Curious about Enhabit executive stock transactions Form 4 ahead of a rate update? Want a red-lined comparison that shows how the new filing differs from last year? Stock Titan provides real-time updates, side-by-side comparisons, and plain-English explanations, so you can decide faster, act sooner, and focus on the fundamentals driving home-health performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit (NYSE:EHAB) director Gregory S. Rush filed a Form 4 disclosing the open-market purchase of 15,773 common shares at $9.51 on 26 Jun 2025. After the trade, Rush directly owns 69,479 shares of EHAB.

No derivative positions or additional transactions were reported in this routine insider filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit (NYSE:EHAB) filed a Form 4 disclosing that director Mark W. Ohlendorf purchased 15,773 shares of common stock on 26-Jun-2025 at an average price of $9.51.

The acquisition lifts the director’s direct holdings to 37,723 shares, representing a roughly 72 % increase in his stake. No dispositions, derivative securities, or Rule 10b5-1 trading-plan indications were reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Enhabit (NYSE:EHAB) filed a Form 4 on 28 June 2025 reporting that director Stuart M. McGuigan acquired 15,773 common shares on 26 June 2025 at $9.51 per share. The open-market purchase, coded "A" for acquisition, raises his direct beneficial ownership to 67,322 shares, a ~23% increase versus his prior holding. No derivative securities or additional insiders were disclosed, and the filing does not reference a Rule 10b5-1 trading plan. Aside from this single transaction, the statement contains no other material events, financial data, or explanatory footnotes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit (NYSE:EHAB) filed a Form 4 reporting that director Erin Hoeflinger acquired 15,773 shares of common stock on 06/26/2025 at $9.51 per share. The transaction, coded “A” (acquisition), is valued at roughly $150 thousand. Following the purchase, Hoeflinger’s direct ownership stands at 70,089 shares. No derivative securities or additional transactions were disclosed in the filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit, Inc. (EHAB) Form 4 filing – insider purchase

Director Charles M. Elson reported an open-market acquisition of 15,773 common shares on 06/26/2025 at $9.51 per share (Transaction Code "A"). After the transaction, his direct beneficial ownership stands at 72,494 shares. No derivative security trades or dispositions were disclosed, and there is no indication the trade was executed under a Rule 10b5-1 plan.

The purchase increases the director’s equity exposure and can be viewed as a personal vote of confidence in Enhabit’s outlook. No other material events or financial metrics were included in the filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Enhabit (NYSE:EHAB) filed a Form 4 on 28 June 2025 reporting that director Tina L. Brown-Stevenson acquired 15,773 shares of common stock on 26 June 2025 at $9.51 per share (transaction code “A”). The purchase, valued at roughly $150 thousand, lifts her direct beneficial ownership to 52,698 shares, an increase of about 30% versus her pre-transaction holdings. No shares were sold and no derivative securities were involved. The filing was signed by Attorney-in-Fact Sarah W. Braley on 27 June 2025 and contains standard Section 16 certifications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Enhabit (NYSE:EHAB) filed a Form 4 disclosing that director Jeffrey Bolton purchased 15,773 common shares on 26 Jun 2025 at $9.51 each. The acquisition lifted his direct ownership to 123,395 shares, approximately a 15 % increase from his pre-transaction position. No dispositions or derivative securities were reported and the filing does not note any Rule 10b5-1 trading plan. Because Form 4 reports relate solely to insider activity, the document contains no financial statements, risk factors or operational updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Enhabit (NYSE:EHAB) filed an 8-K reporting results of its 26 June 2025 annual meeting. Shareholders approved the 2025 Equity & Incentive Compensation Plan, reserving up to 3.3 million shares (≈6.5% of the 50.6 million outstanding) for options, RSUs and performance awards. The plan, administered by the Compensation & Human Capital Committee, includes a $750k annual cap on non-employee director pay and allows performance metrics spanning EBITDA, revenue and quality-of-care. All 10 directors were re-elected, PwC was ratified as auditor and the say-on-pay resolution passed. Support for the equity plan was strong at 31.0 M for vs 0.4 M against. While the plan aligns incentives, it introduces potential dilution and higher stock-based compensation expense.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Enhabit, Inc. (ticker EHAB) has filed a Form S-8 with the SEC to register 3,289,042 shares of common stock for issuance under its newly approved 2025 Equity and Incentive Compensation Plan. The plan was authorized by shareholders at the 2025 Annual Meeting held on June 26, 2025. The filing incorporates the company’s most recent FY-2024 Form 10-K, Q1-2025 Form 10-Q, and prior descriptions of common stock by reference, ensuring that future periodic reports will automatically update the prospectus information.

The document outlines standard Delaware indemnification provisions for directors and officers, confirms the existence of D&O insurance, and lists required exhibits—most notably the full plan text (Exhibit 4.3) and an auditor consent from PwC (Exhibit 23.1). No new financial performance data, earnings guidance, or transactional details are disclosed, and the filing does not alter previously reported financial statements.

For investors, the primary implication is potential dilution from future equity grants as the registered shares become available for employee compensation. The filing is routine for public companies implementing stock-based incentive programs and does not, by itself, signal a change in the company’s operating outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration

FAQ

What is the current stock price of Enhabit (EHAB)?

The current stock price of Enhabit (EHAB) is $9.56 as of June 28, 2025.

What is the market cap of Enhabit (EHAB)?

The market cap of Enhabit (EHAB) is approximately 469.9M.

What services does Enhabit Inc provide?

Enhabit Inc offers comprehensive home health and hospice care services. Their home health services include skilled nursing, therapy, and supportive care, while the hospice segment focuses on symptom management and quality of life for patients with advanced illnesses.

How is Enhabit Inc structured in terms of service segments?

The company operates through two major segments: home health and hospice. The home health segment deals with Medicare-certified nursing and therapy services, whereas the hospice segment provides care focused on patient comfort during life-limiting illnesses.

How does Enhabit generate its revenue?

Enhabit generates most of its revenue from its home health division, offering a broad range of services under Medicare guidelines. The hospice services complement their operations, emphasizing patient-centered care without relying on direct product sales.

What distinguishes Enhabit in the competitive healthcare market?

Enhabit differentiates itself by integrating advanced technologies with expert clinical care in a home-based setting. Its dual focus on home health and hospice care allows for a broader service offer compared to competitors focusing on a single care model.

How does Enhabit ensure the quality of its patient care?

Quality is maintained through a blend of experienced clinical teams, adherence to Medicare guidelines, and the use of advanced health technology. This approach ensures that care is patient-focused, efficient, and tailored to meet individual health needs.

In what ways does Enhabit incorporate technology into its services?

The company integrates innovative technology for scheduling, patient monitoring, and data management. This technological approach enhances operational efficiency and supports clinical decision-making, ensuring quality care delivery in a home setting.

What role does Enhabit play in the US healthcare landscape?

Enhabit serves as a key provider of home health and hospice care, addressing the growing demand for patient-centered services in the comfort of patients' homes. Its focus on both acute rehabilitation and palliative care positions it uniquely within the healthcare ecosystem.

How do Enhabit’s services support the needs of patients and their families?

Enhabit’s services are designed to align with patient preferences by offering care at home, reducing the stress of institutional settings. Their holistic approach not only addresses clinical needs but also provides emotional and social support for both patients and their families.
Enhabit

NYSE:EHAB

EHAB Rankings

EHAB Stock Data

469.92M
49.15M
3.23%
102.53%
2.54%
Medical Care Facilities
Services-home Health Care Services
Link
United States
DALLAS